Table 4 Ongoing clinical trials of epigenetic drugs in combination with immunomodulatory agents for solid cancers (Selected examples)
From: Epigenetic modulation of antitumor immunity for improved cancer immunotherapy
Identifier | Cancer types and conditions | Epigenetic drug | Other immunostimulatory drug | Trial phase | Estimated enrollment |
|---|---|---|---|---|---|
NCT01928576 | Non-small lung cancer | Azacitabine + entinostat or azacitabine alone | Nivolumab (α-PD-1) | II | 120 |
NCT03019003 | Head and neck cancer | Azacitidine | Durvalumab + Tremelimumab | Ib/II | 59 |
NCT03024437 | Metastatic cancer, renal cancer | Entinostat | Atezolizumab and Bevacizumab | I/II | 62 |
NCT03264404 | Pancreatic cancer | Azacitidine | Pembrolizumab (α-PD-1) | II | 31 |
NCT03308396 | Advanced kidney cancer, clear cell renal cell carcinoma | Guadecitabine | Durvalumab (α-PD-L1) | Ib/II | 59 |
NCT03576963 | Colorectal adenocarcinoma, CpG island methylator phenotype, metastatic microsatellite stable colorectal carcinoma and more | Guadecitabine | Nivolumab | Ib/II | 45 |
NCT04651127 | Cervical cancer | Chidamide | Toripalimab (α-PD-1) | Ib/II | 40 |
NCT04562311 | Bladder cancer stage IV | Chidamide | Tislelizumab (α-PD-1) | II | 43 |
NCT03829930 | Prostate adenocarcinoma | Entinostat | Enzalutamide | I | 18 |
NCT03742245 | Relapsed/refractory and/or metastatic breast cancer | Vorinostat | Olaparib | I | 28 |
NCT04553393 | Relapsed and/or Refractory B cell Non-Hodgkin’s Lymphoma with huge tumor burden | Chidamide | Decitabine-primed tandem targeting CD19 and CD20 CAR T Cells | I/II | 80 |
NCT04705818 | Advanced solid Tumors | Tazemetostat | Durvalumab | II | 173 |